Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Decrease in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 68,900 shares, a decrease of 55.2% from the February 29th total of 153,700 shares. Based on an average daily volume of 723,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Bank of America reiterated an “underperform” rating on shares of Achilles Therapeutics in a research report on Thursday, December 14th.

Achilles Therapeutics Stock Performance

Achilles Therapeutics stock opened at $1.25 on Friday. Achilles Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $1.76. The stock’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $0.96. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.55 and a current ratio of 8.55. The stock has a market cap of $50.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in Achilles Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 30,533 shares of the company’s stock worth $90,000 after purchasing an additional 5,000 shares in the last quarter. Bank of America Corp DE grew its position in shares of Achilles Therapeutics by 130.8% in the 1st quarter. Bank of America Corp DE now owns 10,450 shares of the company’s stock worth $31,000 after buying an additional 5,922 shares during the period. Balyasny Asset Management LLC bought a new position in shares of Achilles Therapeutics in the 3rd quarter worth about $39,000. Sei Investments Co. purchased a new position in Achilles Therapeutics during the 2nd quarter valued at about $59,000. Finally, Virtu Financial LLC purchased a new position in Achilles Therapeutics during the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 56.38% of the company’s stock.

About Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.